Digital Pathology and Outcome Prediction Improving the Lives of Patients
Our Mission
Personalized Cancer Treatment
Delivered with AI
DoMore Diagnostics was established to meet the need for novel methods in precision medicine to ensure the right treatment for each cancer patient and is based on prominent international research from leading universities (University in Oslo, Oxford University and University College of London).
The research project was selected as a Lighthouse project by the Norwegian Research Council in 2016 to develop new diagnostic methods for cancer based on artificial intelligence. The project was led by the late Prof. Håvard Danielsen with an aim to utilize new technologies to reduce over- and undertreatment of cancer by providing a new system for cancer prognosis.
The lack of objective and precise methods for cancer prognosis is a limiting step to enable precision medicine to cancer patients worldwide. This is the main drive for DoMore Diagnostics in bringing AI-powered digital biomarkers closer to the clinicians and patients enabling personalized cancer treatment with a great potential to improve patient outcomes at lower health care costs.
Management
Torbjørn Furuseth, MD
Chief Executive Officer (CEO) & Co-founder
-
Torbjørn is an experienced executive with a broad background within life sciences. He has practiced as a physician in radiology and sports medicine, and transitioned into business as a management consultant at McKinsey & Company, where he served several pharma and healthcare clients. After McKinsey he joined pharma and biotech companies in Aker and eventually became EVP Innovation at Aker BioMarine, where he established and led the innovation department. His latest positions are CFO at Targovax and Lytix Biopharma. Torbjørn is a Medical Doctor from Norwegian University of Science and Technology (NTNU).
Sepp De Raedt, PhD
Chief Technology Officer (CTO) & Co-founder
-
Sepp has extensive experience in the development and implementation of novel diagnostic and prognostic methods using machine learning within the fields of radiology and pathology. He was central in the development of DoMore Diagnostics’ technology as Senior Developer at the Institute of Cancer Genetics and Informatics at Oslo University Hospital. The work resulted in the first fully automated method predicting prognosis for cancer patients from histopathology images, published in The Lancet. Sepp earned his MSc at Delft University of Technology (NL) and his PhD at Aarhus University (DK).
Elisabeth M.J. Klaussen, MSc
Head of Quality and Regulatory
-
Elisabeth has broad experience and background from Quality Assurance in R&D and operations in pharma, biotech and medtech companies. She has been working in GE Healthcare, Life Technologies and Medistim as well as start-up companies responsible for Quality Assurance, Risk Management and Regulatory. Elisabeth holds a Cand Scient (MSc) degree in Biology from University of Oslo.
Andreas Berg Storsve, PhD
VP Operations
-
Andreas has a broad background across science and business functions in life sciences, including R&D and partnering strategy, alliance management, business development, and intellectual property. Prior to joining DoMore Diagnostics, Andreas worked as R&D Director at Aker BioMarine ASA and VP Business Development at Circio Holding ASA (formerly Targovax ASA). Andreas holds an MSc in Experimental Psychology from UNSW Sydney, a PhD in Cognitive Neuroscience and NeuroImaging from the University of Oslo, and was a Fulbright Scholar at the Martinos Center, MGH/Harvard Medical School.
Lao Saal, MD, PhD
Medical Director
-
Lao is a medical doctor, cancer scientist and entrepreneur focused on advancing cancer research and improving patient outcomes with precision medicine. He currently serves as Associate Professor and Head of Translational Oncogenomics at Lund University, where his research team is aiming to get a better understanding of cancer biology and guide the implementation of research findings and diagnostic innovations into clinical practice. In 2016, Lao founded SAGA Diagnostics AB, a company that develops cancer biomarkers, particularly circulating tumor DNA, to improve cancer diagnosis and treatment. Lao also provides consulting services in diagnostics, oncology, and health tech, helping to drive innovation in these fields. Lao holds MD and PhD degrees from Columbia University.
Board of Directors
Tomas Nordheim Alme, MD
Chairman
-
Tomas is a pediatrician with more than 20 years of experience in managing projects and companies within healthcare and the ehealth business. He has served as Medical director and Chief Product Officer in DIPS AS (Enterprise EHR systems) and CEO for PatientSky Norway (Cloud EHR systems). In addition to his medical degree, he holds an MBA in Strategic Management from the Norwegian School of Economics.
Øyvind Grotmol, MSc
Director
-
Øyvind is a serial tech entrepreneur. He’s the Founder and CTO of Exabel, providing AI-as-a-Service within financial markets. Previously he was the Director of Research & Innovation at Medallia, VP at Energy Micro, and Senior Scientist at Brain Corp. Within life sciences, he was an early investor and advisor to OncoImmunity.
Mr. Grotmol holds a Master’s degree in Electronics & computer science from Norwegian University of Science and Technology (NTNU).
Yngve Tvedt, MBA
Director
-
Yngve is the founder and Chief Investment Officer of impact investment platform Norselab. He is a well-known figure in the Norwegian venture ecosystem and beyond for his role as a co-founder and an investor in several Norwegian tech success stories. His track record includes technology companies like Documaster, Disruptive Technologies, and Skitude. Yngve and his team launched Norselab's first impact-focused growth fund in 2020, building on Norselab's legacy as a co-founder and seed investor dating back to 2015. Norselab currently manages four funds in growth equity, structured equity, and credit.
Knut Liestøl, Prof
Director
-
Knut Liestøl is professor and previous department head at the Department of Informatics, University of Oslo. He has also been Research Dean at the Faculty of Mathematics and Natural Sciences, and has long experience as board leader for various research organizations. Prof. Liestøl was a co-leader of the DoMore! project and brings a deep understanding on the technical and scientific aspects of the algorithms. Based on a combined background in statistics, mathematical modelling and biology, his scientific work has focused on methodological aspect in studies on disease etiology and epidemiology, in recent years centered on deep learning for medical decision support in cancer.
Ketil F. Widerberg, MBA
Director
-
Ketil brings 20 years of experience from the life science and software industry. In addition to co-founded two start-up companies, he worked for many years in the Norwegian biopharmaceutical company Photocure . He also worked in the software industry for Norwegian KSD Software with logistics technology later acquired by Descartes. Since 2014 Ketil has been Managing Director for Oslo Cancer Cluster, an oncology research and industry cluster.
Ketil holds a few biotech company board positions and was also a member of the health data expert committee from the Ministry of health in 2017. His educational background spans from preclinical medical school to management studies. He also holds an MBA from the University of Cambridge.
Scientific Advisory Board
Dr. John L. Marshall, MD
Oncology CMO for Indivumed
-
John L. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials throughout his career. While he has an interest in many areas of cancer research, his primary focus is on the use of precision medicine in treating cancer. In 2009, he established the Otto J Ruesch Center for the Cure of GI Cancers. In 2015, Dr. Marshall both established and directed the Precision Oncology Alliance. He currently is serving as the Oncology CMO for Indivumed, creating a global precision medicine research network. Dr. Marshall received his training at Duke University, the University of Louisville, and Georgetown University.
Dr. Jeanine Roodhart, MD, PhD
University Medical Centre Utrecht
-
Dr. Jeanine Roodhart is a medical oncologist and associate professor in the Department of Medical Oncology at the University Medical Centre Utrecht, University of Utrecht, in the Netherlands. She is an internationally recognized expert in colorectal cancer, specializing in both clinical and translational research and the design of (early phase) clinical trials. Her research is focused on the personalization of treatment for both non-metastatic and metastatic colorectal cancer. She is the lead investigator on multiple biomarker studies, which are exploring different molecular markers, ctDNA, organoids and digital pathology in order to optimize patient selection. Additionally, she is engaged in optimizing disease models and the development of novel personalized treatments. She is the principal investigator on numerous phase I-III clinical trials.
Dr. Takayuki Yoshino, MD
National Cancer Center Hospital East, Kashiwa
-
Dr. Takayuki Yoshino, M.D. PhD. currently works at the National Cancer Center Hospital East (NCCE) in Kashiwa, Japan, where he is the Deputy Director of Hospital, Head, Division for the Promotion of Drug and Diagnostic Development and Director for the Department of Gastrointestinal Oncology.
Dr. Yoshino has had over 300 peer-review scholar journal publications on CRC. In addition, he holds several professional appointments, serving on a Guidelines Steering Committee member of ESMO, a chair of Pan-Asian adapted ESMO Guideline for CRC, an advisory committee member of ASCO Breakthrough, the Vice President of JSCO and the administrative board & a chair of international affairs committee of JSMO. He was the first Japanese plenary speaker at ASCO 2022 Annual Meeting (5th /JUN/ 2022).
Dr. Jakob Nikolas Kather, MD
Technical University of Dresden
-
Jakob Nikolas Kather is a physician specializing in gastrointestinal oncology, and an AI researcher with a university degree in the field of biomedical engineering. He holds a professorship of „Clinical AI“ at the Technical University of Dresden in Germany. Together with his research team, he has been among the global pioneers for biomarker detection in computational pathology since 2016. Their research has recently been published in Nature Medicine and Nature Cancer, among other venues, and has led to the development of several AI methods which are approved for clinical use.
Dr. Frank A. Sinicrope, MD, FACP
Mayo Clinic Alix School of Mediciner
-
Dr. Frank A. Sinicrope is currently a professor of oncology and medicine at the Mayo Clinic Alix School of Medicine and member of the Mayo Comprehensive Cancer Center in Rochester, MN. Dr. Sinicrope is an internationally recognized expert in gastrointestinal oncology and has a longstanding funded research program with a focus on colorectal cancer. He is a Clinical Investigator of the Mayo Foundation and formerly led the GI Cancer Program within the 3-site Mayo Cancer Center. He is a current member of the National Cancer Institute Colon Cancer Task Force and served 2 terms on the NCI GI Cancer Steering Committee. Currently, he holds multiple committee memberships within the Alliance for Clinical Trials in Oncology including the Executive Committee for the Translational Research Program. Dr. Sinicrope’s research interests include multi-omic analysis of colorectal cancer and predictive and prognostic biomarkers, including the use of deep learning methods. He has over 200 peer reviewed manuscripts and is a principal investigator on active clinical trials. He received his training at MD Anderson Cancer Center and the University of Chicago.
Prof. Marc Peeters, MD
Antwerp University Hospital
-
Marc Peeters is CEO of the Antwerp University Hospital and Professor of oncology at the Antwerp University. Until November 2021, he was head of the oncology department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp.
Dr. Peeters is co-chair of the colorectal task force of EORTC.
His research interests have included the identification of molecular markers and therapy modulation in digestive tumors. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumors, published numerous articles in peer reviewed journals and was author and editor of several chapters in oncology books.
Prof. Marco Novelli, MD
University College London
-
Marco Novelli is professor of gastrointestinal pathology, University College London, Consultant Histopathologist at University College Hospital London and Medical Director at HCA Laboratories, London. He is an internationally recognized expert in gastrointestinal pathology. His research interests include colorectal cancer, Barrett’s oesophagus, inflammatory bowel disease and image analysis/AI. He led the gastrointestinal pathology service at UCLH and was on the UK BCSP National Expert Polyp Panel for many years.
Prof. Hans-Joachim Schmoll, MD
University Hospital of Halle
-
Prof. Dr. med. Hans-Joachim Schmoll is currently leading the clinical oncology research at University Hospital of Halle, Germany.
For decades, Professor Schmoll has been a leader within GI oncology, and was one of the key opinion leaders driving the development of modern testicular cancer treatment. He has been very active in the global oncology community with key positions in ESMO, ASCO, and AIO (Germany). He has been a very active researcher and teacher with numerous publications and book contributions.
Investors
The Norselab Fund was established in 2020 with the goal to create both long-term positive capital returns and net impact through investments and extensive involvement in a portfolio of meaningful technology companies.
Grotmol Solutions AS is an investment firm providing seed and venture capital to startups within the fields of artificial intelligence, life sciences, software and electronics. The firm was established by Øyvind Grotmol in Oslo, Norway in 2008.
Open Positions
There are currently no open positions. Feel free to contact us by using the link below.
